Abstract
Abnormalities in lipid metabolism and enhanced oxidative stress are considered as major risk factors for coronary atherosclerosis. Functional genetic variations in genes whose products are involved in lipid metabolism and antioxidant defense could therefore modulate risk of coronary artery disease (CAD). In this study, we evaluate whether the PPARGC1A Gly482Ser, PPARG3 (−681)C/G, PPARD +294T/C, and CYBA +242C/T gene variants confer the risk of CAD in a Russian population. A total of 313 CAD patients and 132 controls with no clinical sign of CAD were studied. The polymorphic markers were tested using a TaqMan assay. Allele and genotype frequencies in CAD patients and controls were compared using the Yates χ2 test. Association of the genetic markers with metabolic risk factors of arterial atherosclerosis was studied using the analysis of variance test and then adjusted for conventional risk factors in the multiple regression analysis. For CYBA +242C/T, both the allele T and genotype T/T showed significant association with higher risk of CAD (odds ratio =1.49 and 3.89, respectively). The allele C and genotype C/C of the +294T/C marker of PPARD were associated with increased risk of CAD providing an odds ratio of 2.12 and 2.78, respectively. The risk variants of CYBA +242C/T and PPARD +294T/C markers were associated with higher low-density lipoprotein cholesterol and increased total serum cholesterol, respectively. In conclusion, the CYBA +242C/T and PPARD +294T/C variants modulate risk of CAD through their associations with atherogenic serum lipid profiles.
Similar content being viewed by others
References
Finck BN (2007) The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 73:269–277
Berger J, Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435
Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J (1997) The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272:18779–18789
Fajas L, Fruchart JC, Auwerx J (1998) PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55–6
Meirhaeghe A, Fajas L, Gouilleux F, Cottel D, Helbecque N, Auwerx J, Amouyel P (2003) A functional polymorphism in a STAT5B site of the human PPARγ3 gene promoter affects height and lipid metabolism in a French population. Arterioscler Thromb Vasc Biol 23:289–294
Cecil JE, Fischer B, Doney A, Hetherington M, Watt P, Wrieden W, Bolton-Smith C, Palmer CN (2005) The Pro12Ala and C-681G variants of the PPARG locus are associated with opposing growth phenotypes in children. Diabetologia 48:1496–1502
Santos JL, Boutin P, Verdich C, Holst C, Larsen LH, Tourbo S, Dina C, Saris WH, Blaak EE, Hoffstedt J, Taylor MA, Polak J, Clement K, Langin D, Astrup A, Froguel P, Pedersen O, Sorensen TI, Martinez JA (2006) Genotype-by-nutrient interactions assessed in European obese women. A case-only study. Eur J Nutr 45: 454–462
Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M (2003) Peroxisome proliferator-activated receptor (PPAR)α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92:518–524
Cheng L, Ding G, Qin Q, Huang Y, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q (2004) Cardiomyocyterestricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10:1245–1250
Skogsberg J, Kannisto K, Cassel TN, Harnsten A, Eriksson P, Ehrenborg E (2003) Evidence that peroxisome proliferatoractivated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23:637–643
Chen S, Tsybouleva N, Ballantyne CM, Gotto AM, Marian AJ (2004) Effects of PPARα, γ and δ haplotypes on plasma levels of lipids and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14:61–71
Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 3: 108–111
Knutti D, Kralli A (2001) PGC-1, a versatile coactivator. Trends Endocrinol Metab 12:360–365
Huss JM, Kelly DP (2004) Nuclear receptor signaling and cardiac energetics. Circ Res 95:568–578
Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM (2006) Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α. Proc Natl Acad Sci USA 103:10086–1009
Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, Lehman JJ, Kelly DP, Spiegelman BM (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 98:3820–3825
Zhang Y, Xu W, Li X, Tang Y, Xie P, Ji Y, Fan L, Chen Q. Association between PPARGC1A gene polymorphisms and coronary artery disease in a Chinese population. Clin Exp Pharmacol Physiol 35:1172–1177
Iglseder B, Oberkofler H, Felder TK, Klein K, Tregouet DA, Patsch W (2006) Associations of PPARGC1A haplotypes with plaque score but not with intima-media thickness of carotid arteries in middle-aged subjects. Stroke 37:2260–2265
Esterbauer H, Oberkofler H, Linnemayr V, Iglseder B, Hedegger M, Wolfsgruber B, Fastner G, Krempler F, Patsch W (2002) Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes 51:1281–1286
Hara K, Tobe K, Okada T, Kadowaki H, Akanuma Y, Ito C, Kimura S, Kadowaki T (2002) A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 45:740–743
Oberkofler H, Holz B, Esterbauer H, Xie M, Iglseder B, Krempler F, Paulweber B, Patsch W (2003) Peroxisome proliferatoractivated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men. Hypertension 41:368–372
Zhang SL, Lu WS, Yan L, Wu MC, Xu MT, Chen LH, Cheng H (2007) Association between peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene polymorphisms and type 2 diabetes in southern Chinese population: role of altered interaction with myocyte enhancer factor 2C. Chin Med J (Engl) 120:1878–1885
Puddu P, Puddu GM, Cravero E, Rosati M, Muscari A (2008) The molecular sources of reactive oxygen species in hypertension. Blood Press 17:70–77
Fukui T, Yoshiyama M, Hanatani A, Omura T, Yoshikawa J, Abe J (2001) Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem Biophys Res Commun 281:1200–1206
Zhang C, Hein TW, Wang W, Kuo L (2003) Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 92:322–329
Koabayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H (2008) Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in Dahl salt-sensitive hypertensive rats. Am J Hypertens 21:576–581
San Jose G, Fortuno A, Beloqui O, Diez J, Zalba G (2008) NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clin Sci (Lond) 114:173–182
Guzik TJ, West NE, Black E, McDonalds D, Ratnatunga C, Pillai R, Channon KM (2000) Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102:1744–1747
De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D (2004) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 173:381–391
Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined — a consensus document of The Joint Euro pean Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502
Kuroda J, Kitazono T, Ago T, Ninomiya T, Ooboshi H, Kamouchi M, Kumai Y, Hagiwara N, Yoshimura S, Tamaki K, Kusuda K, Fujii K, Nagao T, Okada Y, Toyoda K, Nakane H, Sigumori H, Yamashita Y, Wakuwaga Y, Asano K, Tanizaki Y, Kiyohara Y, Ibayashi S, Iida M (2007) NAD(P)H oxidase p22phox C242T polymorphism and ischemic stroke in Japan: the Fukuoka Stroke Registry and the Hisayama study. Eur J Neurol 14:1091–1097
Ling C, Del Guerra S, Lupi R, Ronn T, Granhall C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S (2008) Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 51:615–622
Vanttinen M, Nuutila P, Kuulasmaa T, Pihlajamaki J, Hallsten J, Hallsten K, Virtanan KA, Lautamaki R, Peltoniemi P, Takala T, Viljanen AP, Knuuti J, Laakso M (2005) Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor δ gene are associated with skeletal muscle glucose uptake. Diabetes 54:3587–3591
Cahilly C, Ballantyne CM, Lim DS, Gotto A, Marian AJ (2000) A variant of p22phox, involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 86:391–395
Nasti S, Spallarossa P, Altieri P, Garibaldi S, Fabbi P, Polito L, Bacino L, Brunelli C, Barsotti A, Ghigliotti G (2006) C242T polymorphism in CYBA gene (p22phox) and risk of coronary artery disease in a population of Caucasian Italians. Dis Markers 22:167–173
He MA, Cheng LX, Jiang CZ, Zeng HS, Wang J, Wang F, Chen Y, Yang M, Tan H, Zheng HY, Hu FB, Wu TC (2007) Associations of polymorphism of P22phox C242T, plasma levels of vitamin E, and smoking with coronary heart disease in China. Am Heart J 640:e1–e6
Macias-Reyes A, Rodriguez-Esparragon F, Caballero-Hidalgo A, Hernandez-Trujilo Y, Medina A, Rodriguez-Perez JC (2008) Insight into the role of CYBA A640G and C242T gene variants and coronary heart disease risk. A case-control study. Free Radic Res 42:89–92
Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M (1999) Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100: 1494–1498
Hathaway CA, Heistad DD, Piegors DJ, Miller FJ Jr (2002) Regression of atherosclerosis in monkeys reduces vascular superoxide levels. Circ Res 90:277–283
De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK (1998) Tumor necrosis factor α activates a p22phox based NADH oxidase in vascular smooth muscle. Biochem J 329:653–657
Rupin A, Paysant J, Sansilvestri-Morel P, Lembrez N, Lacoste JM, Cordi A, Verbeuren TJ (2004) Role of NADPH oxidase-mediated superoxide production in the regulation of E-selectin expression by endothelial cells subjected to anoxia/reoxygenation. Cardiovasc Res 63:323–330
Zak I, Sarecka B, Krauze J (2008) Synergistic effects between 561A > C and 98G > T polymorphisms of E-selectin gene and hypercholesterolemia in determining the susceptibility to coronary artery disease. Heart Vessels 23:257–263
Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T (1999) Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis. Circulation 99:2027–2033
Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR (2006) Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J Lipid Res 47:2248–2258
Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, Palmer CN (2001) The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276:44258–44265
Dickhout JG, Basseri S, Austin RC (2008) Macrophage function and its impact on atherosclerotic lesion composition, progression, and stability: the good, the bad, and the ugly. Artherioscler Thromb Vasc Biol 28:1413–1415
Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302:453–457
Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, Tall AR, Matsushima GK, Tabas I (2006) Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem 281: 6707–6717
Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: A review of their structure and role in coronary syndrome. Cardiovasc Res 59:812–823
Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S (2001) The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50:3–11
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nikitin, A.G., Chistiakov, D.A., Minushkina, L.O. et al. Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. Heart Vessels 25, 229–236 (2010). https://doi.org/10.1007/s00380-009-1159-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-009-1159-9